Pulmonary granulomatous disease

Pulmonary granulomatous disease is characterized by the formation of granulomas, localized clusters of immune cells, in response to infections, inflammation, or environmental triggers. These granulomas may develop in conditions such as sarcoidosis, fungal infections, tuberculosis, and certain occupational exposures. Clinical manifestations vary, with some patients remaining asymptomatic and others experiencing chronic cough, fever, fatigue, or hemoptysis. Accurate diagnosis requires careful evaluation of clinical history, imaging studies such as high-resolution CT, and microbiological or histopathological confirmation. Differentiating between infectious and non-infectious causes is critical for guiding appropriate treatment and avoiding unnecessary interventions.

Management strategies are tailored to the underlying cause and severity. Infectious granulomas require targeted antimicrobial therapy, while non-infectious granulomatous conditions may benefit from anti-inflammatory or immunosuppressive agents. Supportive care, including oxygen therapy, pulmonary rehabilitation, and prevention of secondary infections, is essential to maintain lung function. Regular monitoring and follow-up imaging allow clinicians to track disease progression and adjust treatment accordingly. Collaborative care involving pulmonologists, infectious disease specialists, and radiologists ensures comprehensive evaluation and management. Emerging research into molecular pathways and immune responses within granulomas offers the potential for novel therapeutic approaches, aiming to reduce tissue damage and improve long-term pulmonary outcomes.